7-Day Supply

5 volatile drug launches to watch in 2024
5 volatile drug launches to watch in 2024
Marc Iskowitz
January 19, 2024
1:57 pm

Not all of these upcoming drug launches are consensus analyst picks, but they’re all expected to create volatility in some way. Ignore them at your peril.

JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage
JPM24: ‘Diabesity’ duopoly between Novo, Lilly takes center stage
Marc Iskowitz
January 11, 2024
9:36 am

The CEOs of Eli Lilly and Novo Nordisk — rivals in the GLP-1 obesity market — addressed nagging questions at the 2024 J.P. Morgan Healthcare Conference.

The pharma commercialization year in review
The pharma commercialization year in review
Marc Iskowitz
December 20, 2023
4:41 pm

Amid all of the acquiring, investing and reorganizing, a few trends in pharma commercialization bubbled to the surface.

Inside Bayer’s embrace of generative AI
Inside Bayer’s embrace of generative AI
Marc Iskowitz
December 15, 2023
10:43 am

In this wide-ranging interview, Bayer’s head of digital transformation Saskia Steinacker shares her top tips for implementing a genAI roadmap in commercial.

Pharma has little visibility into the growing area of PBM fees
Pharma has little visibility into the growing area of PBM fees
Marc Iskowitz
December 11, 2023
8:00 am

Lack of consistent insight into PBM service fees puts drugmakers at a disadvantage when calculating prices.

Signs point to upturn in pharma commercialization M&A in 2024
Signs point to upturn in pharma commercialization M&A in 2024
Marc Iskowitz
November 27, 2023
10:41 am

Several factors are coming together to create the right conditions for a major upturn in dealmaking in the pharma commercialization sector.

Pharma CEOs ‘find their voice’ on Israel-Hamas conflict
Pharma CEOs ‘find their voice’ on Israel-Hamas conflict
Marc Iskowitz
November 1, 2023
10:05 am

Their condemnation of Hamas’ terror attack on October 7 highlights the heightened expectations for life-sci leaders to weigh in on social issues, says former CEO.

Does private equity have a real-world data strategy?
Does private equity have a real-world data strategy?
Marc Iskowitz
October 20, 2023
4:25 pm

As the pharma services sector continues to consolidate, RWD is emerging as a critical piece of the commercialization offering.

Is Medicare’s drug-price law affecting the way pharma brands advertise?
Is Medicare’s drug-price law affecting the way pharma brands advertise?
Marc Iskowitz
September 11, 2023
4:25 pm

Eliquis, the biggest drug on Medicare’s negotiation list, halved TV spend this year. Is the law prompting drugmakers to shorten their DTC ad cycles?

Drugmakers in crowded immunology space ramp up branded push
Drugmakers in crowded immunology space ramp up branded push
Marc Iskowitz
August 28, 2023
5:17 pm

Stalwarts battling a new wave of upstarts are gaining an edge through more aggressive marketing, an analysis of their online activity shows.

  • From Our Partners